Neuroendocrine Tumor Markers

Tumor markers used in the diagnosis and follow-up of patients with neuroendocrine tumors are in most instances not specific for a given tumor and circulate under normal conditions in the serum, making their use as an early diagnostic tool difficult (low sensitivity). By combining hormone measurements with tissue responsiveness, demonstrations of inappropriate secretions of PTH, insulin, and gastrin during hypercalcemia, hypoglycemia, and hyperacidity, respectively, become highly sensitive and specific diagnostic tests. The application of polyclonal antibodies in RIAs of hormones, such as ACTH, insulin, and gastrin, increase the diagnostic level of hormone measurements in patients with neuroendocrine tumors. Other markers, such as chromogranin A, neuron-specific enolase, and alpha-subunit, as well as peptide receptor visualization, are of increasing importance in the diagnosis and follow-up of neuroendocrine and non-neuroendocrine tumors.

[1]  B. Milleron,et al.  Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. , 1985, Chest.

[2]  W. Wiersinga,et al.  [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? , 1994, The Journal of clinical endocrinology and metabolism.

[3]  S. Lamberts,et al.  Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. , 1985, The New England journal of medicine.

[4]  A. Klibanski,et al.  Clinical review 45: Clinically nonfunctioning pituitary adenomas. , 1993, The Journal of clinical endocrinology and metabolism.

[5]  J. Arends,et al.  Endocrine cells in colorectal adenocarcinomas: Incidence, hormone profile and prognostic relevance , 1993, International journal of cancer.

[6]  S. Lamberts,et al.  Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine. , 1989, The Journal of clinical endocrinology and metabolism.

[7]  Koper,et al.  Sporadic endocrine tumours and their relationship to the hereditary endocrine neoplasia syndromes , 2000, European journal of clinical investigation.

[8]  M. Pandian,et al.  Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. , 1993, British Journal of Cancer.

[9]  R. Bouillon,et al.  Chromogranin A: its clinical value as marker of neuroendocrine tumours , 1998, European journal of clinical investigation.

[10]  E P Krenning,et al.  Peptide receptor imaging and therapy. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  L. Eiden,et al.  Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway , 1995, Regulatory Peptides.

[12]  B. Clayton,et al.  A VARIANT OF PHENYLKETONURIA , 1975, The Lancet.

[13]  E. Wilander,et al.  Malignant Carcinoid Tumors An Analysis of 103 Patients with Regard to Tumor Localization, Hormone Production, and Survival , 1987, Annals of surgery.

[14]  D. Venzon,et al.  Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study , 1996, Annals of Internal Medicine.

[15]  M. Girelli,et al.  Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow‐up of medullary thyroid carcinoma , 1984, Cancer.

[16]  S. Pauker,et al.  Interpreting hoofbeats: can Bayes help clear the haze? , 1992, The New England journal of medicine.

[17]  J. Reubi.  The role of peptides and their receptors as tumor markers. , 1993, Endocrinology and metabolism clinics of North America.

[18]  A. D. Smith,et al.  Secretion of a Chromaffin Granule Protein, Chromogranin, from the Adrenal Gland after Splanchnic Stimulation , 1967, Nature.

[19]  E. Theodorsson.  Regulatory peptides as tumour markers. , 1989, Acta oncologica.

[20]  J. Feldman.  Carcinoid tumors and syndrome. , 1987, Seminars in oncology.

[21]  N. Valli,et al.  Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. , 1999, The Journal of clinical endocrinology and metabolism.

[22]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[23]  H. Gerdes,et al.  The granin protein family: Markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors , 1994, Journal of endocrinological investigation.

[24]  S. Wells,et al.  Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease , 1984, Cancer.

[25]  E. Seregni,et al.  Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors , 1999, Cancer.

[26]  J. Norton,et al.  Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1. , 1997, Surgery.

[27]  A. Lindblom,et al.  Tumour markers in malignancies , 2000, BMJ : British Medical Journal.

[28]  U. Hellman,et al.  A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. , 1990, Acta endocrinologica.

[29]  J. Scammell.  Granins markers of the regulated secretory pathway , 1993, Trends in Endocrinology & Metabolism.

[30]  S. Lamberts,et al.  Pituitary tumour localization in patients with Cushing's disease by magnetic resonance imaging. Is there a place for petrosal sinus sampling? , 1994, Clinical endocrinology.

[31]  D. O'Connor,et al.  Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. , 1990, The Journal of clinical investigation.

[32]  D. London,et al.  ACTH precursors characterize the ectopic ACTH syndrome , 1994, Clinical endocrinology.

[33]  J. Reubi,et al.  Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. , 1989, The American journal of pathology.

[34]  A. Vinik,et al.  Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog. , 1990, The Journal of clinical endocrinology and metabolism.

[35]  D. Venzon,et al.  Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas , 1999, Cancer.

[36]  E. Krenning,et al.  Octreotide scintigraphy for the detection of paragangliomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  M. Gillman,et al.  Familial carotid body tumors: Case report and epidemiologic review , 1980, Cancer.

[38]  U. Studer,et al.  Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. , 1993, The Journal of clinical endocrinology and metabolism.

[39]  R. Merrell,et al.  Localization studies in patients with hyperparathyroidism. , 1995, The Surgical clinics of North America.

[40]  H. Bruining,et al.  Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. , 1990, The Journal of clinical endocrinology and metabolism.

[41]  O. Cussenot,et al.  Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. , 1996, The Journal of urology.

[42]  Anne White,et al.  ACTH precursors: biological significance and clinical relevance , 1998, Clinical endocrinology.

[43]  D. O'Connor,et al.  Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. , 1989, Clinical chemistry.

[44]  M. Grossmann,et al.  Alpha‐subunit and human chorionic gonadotropin‐β immunoreactivity in patients with malignant endocrine gastroenteropancreatic tumours , 1994, European journal of clinical investigation.

[45]  B. Eriksson,et al.  Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. , 1991, Acta oncologica.

[46]  E. Krenning,et al.  Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. , 1997, The Journal of clinical endocrinology and metabolism.

[47]  C. Cordon-Cardo,et al.  Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. , 1994, The Journal of urology.

[48]  J. Doppman,et al.  Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  M. Stridsberg,et al.  Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma. , 1996, The Journal of endocrinology.

[50]  J. Doppman,et al.  Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. , 1999, The Journal of clinical endocrinology and metabolism.

[51]  S. Lakhani,et al.  Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. , 1999, Cancer research.

[52]  S. Lamberts,et al.  Drug therapy : octreotide , 1996 .

[53]  E. P. Krenning,et al.  LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN , 1989, The Lancet.

[54]  T. Adrian,et al.  Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors. , 1986, The New England journal of medicine.

[55]  R. Mårvik,et al.  Neuroendocrine differentiation in colorectal carcinomas. , 1995, European journal of gastroenterology & hepatology.

[56]  P. Ladenson,et al.  Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. , 1998, The Journal of clinical endocrinology and metabolism.

[57]  H. Heshmati,et al.  Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). , 2000, The Journal of clinical endocrinology and metabolism.

[58]  W. Huttner,et al.  Argyrophilia and Granin (Chromogranin/Secretogranin) Expression in Female Breast Carcinomas Their Relationship to Survival and Other Disease Parameters , 1992, The American journal of surgical pathology.

[59]  E. Krenning,et al.  Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas , 1999, European Journal of Nuclear Medicine.

[60]  J. Doppman,et al.  Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. , 1997, Gastroenterology.

[61]  R. Bouillon,et al.  A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas. , 1993, The Journal of clinical endocrinology and metabolism.

[62]  G. Irvine,et al.  Serum neurone-specific enolase levels in patients with neuroendocrine and carcinoid tumours. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[63]  J. Foekens,et al.  High incidence of somatostatin receptors in human meningiomas: biochemical characterization. , 1986, The Journal of clinical endocrinology and metabolism.

[64]  J. Polak.  Diagnostic histopathology of neuroendocrine tumours , 1993 .

[65]  K. Lucas,et al.  Flushing in the carcinoid syndrome and plasma kallikrein , 1986, Cancer.

[66]  T. H. van der Kwast,et al.  The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. , 1997, The Journal of urology.

[67]  P. Pour,et al.  Endocrine aspects of exocrine cancer of the pancreas. Their patterns and suggested biologic significance. , 1993, American journal of clinical pathology.

[68]  A. Shulkes,et al.  Expression of neurotensin in endocrine tumors. , 1990, The Journal of clinical endocrinology and metabolism.

[69]  D. Schmechel,et al.  Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells , 1978, Nature.

[70]  V. Reuter,et al.  Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma , 1993, Cancer.

[71]  G. Baldwin,et al.  Gastrin, gastrin receptors and colorectal carcinoma , 1998, Gut.

[72]  E. Krenning,et al.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors. , 1991, Endocrine reviews.

[73]  T. H. van der Kwast,et al.  Androgen‐independent growth is induced by neuropeptides in human prostate cancer cell lines , 2000, The Prostate.

[74]  E. Krenning,et al.  Somatostatin-receptor imaging in the localization of endocrine tumors. , 1990, The New England journal of medicine.

[75]  H. Wilson,et al.  Prohormones: their Clinical Relevance , 1998, Trends in Endocrinology & Metabolism.

[76]  D. O'Connor,et al.  Secretion of chromogranin A by peptide-producing endocrine neoplasms. , 1986, The New England journal of medicine.

[77]  R. Bouillon,et al.  Serum chromogranin A in the differential diagnosis of Cushing's syndrome. , 1994, European journal of endocrinology.

[78]  H. Bonjer,et al.  The value of plasma markers for the clinical behaviour of phaeochromocytomas. , 2002, European journal of endocrinology.

[79]  B. Skogseid,et al.  Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. , 1999, The Journal of clinical endocrinology and metabolism.

[80]  C. Haskell,et al.  Clinical use of tumor markers in oncology. , 1991, Current problems in cancer.

[81]  P. Harris.  Biochemical markers for clinically non‐functioning pituitary tumours , 1998, Clinical endocrinology.

[82]  T. van Vroonhoven,et al.  Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. , 1994, The New England journal of medicine.

[83]  E. Wilander,et al.  A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience. , 1987, The Journal of clinical endocrinology and metabolism.

[84]  P. Scardino,et al.  Elevated plasma chromogranin-A concentrations in prostatic carcinoma. , 1991, The Journal of urology.

[85]  K. Østerlind,et al.  Chromogranin A, a significant prognostic factor in small cell lung cancer , 1999, British Journal of Cancer.

[86]  E. Krenning,et al.  In vivo somatostatin receptor imaging in medullary thyroid carcinoma. , 1993, The Journal of clinical endocrinology and metabolism.

[87]  B. Pernow,et al.  Determination of 5-hydroxytryptamine, 5-hydroxyindole acetic acid and histamine in thirty-three cases of carcinoid tumor (argentaffinoma). , 1957, The American journal of medicine.

[88]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. , 1992 .

[89]  M. Sandler,et al.  Prostaglandins in amine-peptide-secreting tumours. , 1968, Lancet.

[90]  W. Huttner,et al.  Synaptophysin and chromogranins/secretogranins widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis , 1989, Virchows Archiv. B, Cell pathology including molecular pathology.

[91]  P. di Sant'Agnese,et al.  Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. , 1996, Urology.

[92]  M. Gratzl,et al.  Markers for neural and endocrine cells , 1991 .

[93]  D. O'Connor,et al.  Elevated serum chromogranin A concentrations in small-cell lung carcinoma. , 1986, Annals of internal medicine.

[94]  E. Grouzmann,et al.  Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. , 1989, The Journal of clinical endocrinology and metabolism.

[95]  W. Odell.  Endocrine/metabolic syndromes of cancer. , 1997, Seminars in oncology.

[96]  H. Höfler,et al.  Revised classification of neuroendocrine tumors of the lung, pancreas and gut. , 1994, Digestion.

[97]  P. Marangos,et al.  Serum markers for pancreatic islet cell and intestinal carcinoid tumors: a comparison of neuron-specific enolase, beta-human chorionic gonadotropin and pancreatic polypeptide. , 1983, Surgery.

[98]  H. Bonjer,et al.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. , 2001, The Journal of clinical endocrinology and metabolism.

[99]  V. Go,et al.  Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea. , 1991, Gastroenterology.

[100]  R. Benya,et al.  Assessment and Prediction of Long-term Cure in Patients with the Zollinger-Ellison Syndrome: The Best Approach , 1993, Annals of Internal Medicine.

[101]  T. Adrian,et al.  PANCREATIC POLYPEPTIDE IN INSULINOMAS, GASTRINOMAS, VIPOMAS, AND GLUCAGONOMAS , 1976, The Lancet.

[102]  L. Deftos.  Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. , 1991, Endocrine reviews.

[103]  T. O'Dorisio,et al.  Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. , 1986, The American journal of medicine.

[104]  E. Bravo,et al.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. , 1994, Endocrine reviews.

[105]  E. Krenning,et al.  The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. , 1996, Annals of surgery.

[106]  A. Shabsigh,et al.  Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. , 1999, The Journal of urology.

[107]  D. Macgillivray,et al.  The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism. , 1999, Surgical oncology clinics of North America.

[108]  A. Pinchera,et al.  Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[109]  M. Wick,et al.  Neuroendocrine neoplasia. Current concepts. , 2000, American journal of clinical pathology.

[110]  Y. Hamada,et al.  Endocrine cells and prognosis in patients with colorectal carcinoma , 1992, Cancer.

[111]  S. Stewart,et al.  Summary , 1966, National Institute Economic Review.

[112]  S. Libutti,et al.  Forty-eight-hour fast: the diagnostic test for insulinoma. , 2000, The Journal of clinical endocrinology and metabolism.